Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
To assess whether the addition of 6 cycles of cabazitaxel to
abiraterone acetate in patients with CRPC that have previously
received docetaxel and ADT for HSPC can improve PFS compared to
abiraterone acetate alone.
Age ≥ 18 years Histologically confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate). Previous chemotherapy with at least 3 cycles of docetaxel for hormone-sensitive metastatic prostate cancer. Metastatic disease as evidenced by the presence of soft tissue and/or bone metastases on imaging studies (CT/MRI of abdomen/pelvis, bone scintigraphy or NaF PET/CT). Ability to swallow abiraterone acetate tablets as a whole.
Exclusion Criteria:
Any prior chemotherapy or AR-directed therapy for CRPC, (e.g. docetaxel, cabazitaxel, mitoxantrone, abiraterone Pure small cell or other variant (non-adenocarcinoma) prostate cancer histology for which treatment with abiraterone would not be considered appropriate. Patients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy. Any medical condition for which prednisone (corticosteroid) is contraindicated. Active infection requiring treatment with antibiotics.